Cannabidiol Patch With 14-Hour Delivery OK In UK, But Not Pain, Anxiety And Diabetes Claims
UK advertising regulator says an ad catalog retailer claiming a CBD patch could reduce chronic pain, anxiety and diabetes violated advertising codes. The agency says claims including the product penetrated quickly through skin were medicinal and not approved by the UK or EU.
You may also be interested in...
A report FDA submitted to Congress earlier in March on determining an enforcement discretion policy for CBD-containing non-drug products did little to indicate it is approaching a decision. It's likely that FDA officials are reasonably confident of CBD's safety in food and supplements because the agency has allowed the market to proliferate.
BREAKING NEWS: UK food regulator, FSA, has given CBD firms until the 31 March 2021 to submit valid novel food applications under new EU rules. FSA says it will not take products off shelves until then, but has also warned some consumers against taking CBD due to "potential adverse health effects."
The agency announces that it cannot conclude cannabidiol is GRAS, potentially heading off GRAS notifications and making NDI notifications a likelier future for CBD use in the supplement sector if any “lawful pathway” is to be found. In addition to a barrage of warning letters to marketers of CBD products, the FDA issued a stark warning to consumers about potential hazards.